Tonix Q3 TONMYA Sales Hit $15M, But Net Loss Widens to $53.3M
TNXP is trading near its 52-week low of $4.55 (4.4% below the low).
Summary
TONMYA net sales came in at roughly $15.0 million for Q3, up 37% from Q2, with total product revenue of $17.2 million versus $3.3 million a year ago. Prescriptions grew 28% quarter-over-quarter to 16,375 and coverage now reaches about 166 million lives, roughly 53% of the U.S. total. The problem is the cost side: R&D jumped to $25.8 million from $9.3 million and SG&A to $45.6 million from $25.7 million, pushing the net loss to $53.3 million, or $2.89 per share. Cash fell to about $163 million from $207.6 million at year-end, and management now says funding lasts into early Q3 2027, versus the prior early Q2 2027 runway. The Dr. Reddy's Paragraph IV challenge to TONMYA patents remains unresolved and is the biggest overhang on the franchise. Conference call is today at 8:30 a.m. ET.
At the time of this announcement, TNXP was trading at $4.35 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $81.3M. The 52-week trading range was $4.55 to $20.56. This news item was assessed with negative market sentiment and an importance score of 7 out of 10. Source: GlobeNewswire.